US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Jyong Biotech

2.16

0.0000

Volume:- -

Turnover:137.51K

Market Cap:164.22M

PE:-33.76

High:2.16

Open:2.16

Low:2.16

Close:2.16

52wk High:67.00

52wk Low:1.43

Shares:76.03M

Float Shares:28.74M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0640

EPS(LYR):-0.0640

ROE:--

ROA:-12.01%

PB:-6.59

PE(LYR):-33.76

Loading ...

Overview Company News Filings

Jyong Biotech to Join StockFan Virtual Investor Non-Deal Roadshow

Jyong Biotech CEO targets 2029-2030 FDA NDA filing for Botreso, PharmaBoardroom interview says

Jyong Biotech FY25 net loss widens 55% to US$4.67 million

Jyong Biotech delays annual Form 20-F filing, cites audit completion needs

Jyong Biotech files Form 3; CFO Zhang Wei reports no beneficial ownership

Jyong Biotech files Form 3 showing CEO Fu-Feng Kuo as 10% owner

Jyong Biotech director Chi Pang-Chieh files initial beneficial ownership statement

Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/MENS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MENS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MENS\",,,,,undefined,":{"symbol":"MENS","market":"US","secType":"STK","nameCN":"Jyong Biotech","latestPrice":2.16,"timestamp":1789047005782,"preClose":2.16,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":28737800,"shares":76027667,"eps":-0.063976,"marketStatus":"Trading","change":0,"latestTime":"09-10 09:30:05 EDT","open":2.16,"high":2.16,"low":2.16,"amount":137512.9942868,"amplitude":0,"askPrice":2.4,"askSize":38,"bidPrice":2.08,"bidSize":1539,"shortable":3,"etf":0,"ttmEps":-0.063976,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"listingDate":1744862400000,"exchange":"NASDAQ","adjPreClose":2.16,"postHourTrading":{"tag":"盘后","latestPrice":2.16,"preClose":2.16,"latestTime":"19:30 EDT","volume":6,"amount":12.96,"timestamp":1788996606935,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0,"impliedVol":1.6726,"impliedVolPercentile":0.6415},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MENS\",,,,,undefined,":{"symbol":"MENS","floatShares":28737800,"roa":"-12.01%","roe":"--","lyrEps":-0.063976,"shares":76027667,"dividePrice":0,"high":2.16,"amplitude":0,"preClose":2.16,"low":2.16,"week52Low":1.43,"pbRate":"-6.59","week52High":67,"institutionHeld":0,"latestPrice":2.16,"committee":0.951807,"eps":-0.063976,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.063976,"open":2.16,"prevYearClose":3.95,"prevWeekClose":2.39,"prevMonthClose":2.23,"prevQuarterClose":2.07,"fiveDayClose":2.25,"twentyDayClose":2.04,"sixtyDayClose":1.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MENS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-14","symbol":"MENS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2026-01-09","symbol":"MENS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1767934800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MENS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MENS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MENS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MENS","date":"2026-09-08","current":-33.762661,"percent":0.764706,"low":-1671.474987,"twenty":-992.924424,"median":-74.378344,"eighty":-35.895362,"high":-24.792147,"avg":-407.170844,"sd":515.053159,"marketCap":177417847},"quantilePoints":[{"date":"2025-06-20","current":-203.776286,"twenty":-230.665817,"median":-203.776286,"eighty":-192.159849,"marketCap":615200608},{"date":"2025-06-27","current":-224.00343,"twenty":-215.938323,"median":-202.579037,"eighty":-189.726725,"marketCap":676266355},{"date":"2025-07-03","current":-195.234603,"twenty":-221.003604,"median":-203.808474,"eighty":-195.578845,"marketCap":589413267},{"date":"2025-07-11","current":-224.00343,"twenty":-224.00343,"median":-203.776286,"eighty":-193.660924,"marketCap":676266355},{"date":"2025-07-18","current":-270.722038,"twenty":-248.100396,"median":-208.75841,"eighty":-195.234603,"marketCap":817309833},{"date":"2025-07-25","current":-289.655369,"twenty":-270.672861,"median":-224.00343,"eighty":-195.578845,"marketCap":874469558},{"date":"2025-08-01","current":-468.661403,"twenty":-288.081689,"median":-239.863168,"eighty":-197.84101,"marketCap":1414888775},{"date":"2025-08-08","current":-841.426716,"twenty":-379.453451,"median":-248.592171,"eighty":-201.860688,"marketCap":2540267255},{"date":"2025-08-15","current":-973.468255,"twenty":-555.508836,"median":-270.599094,"eighty":-203.789161,"marketCap":2938900662},{"date":"2025-08-22","current":-1061.25006,"twenty":-894.144977,"median":-285.475283,"eighty":-204.775034,"marketCap":3203913932},{"date":"2025-08-29","current":-1365.166899,"twenty":-1022.00643,"median":-288.917707,"eighty":-208.610878,"marketCap":4121438867},{"date":"2025-09-05","current":-1355.085515,"twenty":-1114.607628,"median":-347.684797,"eighty":-209.004298,"marketCap":4091003169},{"date":"2025-09-12","current":-1584.006693,"twenty":-1218.618003,"median":-441.613788,"eighty":-224.00343,"marketCap":4782116207},{"date":"2025-09-19","current":-1318.177851,"twenty":-1286.23704,"median":-523.494295,"eighty":-224.00343,"marketCap":3979578933},{"date":"2025-09-26","current":-1509.21812,"twenty":-1347.708893,"median":-786.347936,"eighty":-227.445854,"marketCap":4556329503},{"date":"2025-10-03","current":-1324.54586,"twenty":-1347.708893,"median":-940.396399,"eighty":-233.593039,"marketCap":3998803952},{"date":"2025-10-10","current":-1377.018254,"twenty":-1355.085515,"median":-1003.088768,"eighty":-246.133297,"marketCap":4157218108},{"date":"2025-10-17","current":-1489.859372,"twenty":-1369.101097,"median":-1041.824955,"eighty":-247.362734,"marketCap":4497885445},{"date":"2025-10-24","current":-1542.331766,"twenty":-1407.075256,"median":-1114.607628,"eighty":-248.592171,"marketCap":4656299601},{"date":"2025-10-31","current":-1146.49633,"twenty":-1407.075256,"median":-1138.789207,"eighty":-259.411217,"marketCap":3461272420},{"date":"2025-11-07","current":-953.163578,"twenty":-1404.508884,"median":-1114.607628,"eighty":-270.476151,"marketCap":2877600843},{"date":"2025-11-14","current":-974.050648,"twenty":-1403.763891,"median":-1074.835074,"eighty":-270.722038,"marketCap":2940658906},{"date":"2025-11-21","current":-835.482773,"twenty":-1377.018254,"median":-1042.570424,"eighty":-274.164462,"marketCap":2522322492},{"date":"2025-11-28","current":-692.839373,"twenty":-1370.684528,"median":-1023.721118,"eighty":-283.213119,"marketCap":2091682067},{"date":"2025-12-05","current":-743.528724,"twenty":-1368.302652,"median":-1011.760759,"eighty":-287.245672,"marketCap":2244713218},{"date":"2025-12-12","current":-678.575033,"twenty":-1365.754127,"median":-990.09803,"eighty":-288.081689,"marketCap":2048618024},{"date":"2025-12-19","current":-84.821879,"twenty":-1357.495212,"median":-973.759452,"eighty":-287.245672,"marketCap":256077253},{"date":"2025-12-26","current":-90.680447,"twenty":-1355.282225,"median":-962.970312,"eighty":-270.623683,"marketCap":273764270},{"date":"2026-01-02","current":-100.614541,"twenty":-1352.134866,"median":-921.074128,"eighty":-247.854509,"marketCap":303755300},{"date":"2026-01-09","current":-101.888143,"twenty":-1343.873049,"median":-841.426716,"eighty":-225.3804,"marketCap":307600304},{"date":"2026-01-16","current":-90.347797,"twenty":-1334.971925,"median":-784.679158,"eighty":-205.709406,"marketCap":266074262},{"date":"2026-01-23","current":-82.514173,"twenty":-1329.160825,"median":-777.915972,"eighty":-197.84101,"marketCap":243004240},{"date":"2026-01-30","current":-66.846925,"twenty":-1324.749636,"median":-757.793064,"eighty":-192.283954,"marketCap":196864194},{"date":"2026-02-06","current":-43.346053,"twenty":-1323.272258,"median":-744.420245,"eighty":-110.344859,"marketCap":127654126},{"date":"2026-02-13","current":-38.384758,"twenty":-1315.070263,"median":-743.019283,"eighty":-99.712528,"marketCap":113043111},{"date":"2026-02-20","current":-51.963039,"twenty":-1302.639909,"median":-725.95302,"eighty":-91.39228,"marketCap":153031151},{"date":"2026-02-27","current":-60.057784,"twenty":-1286.23704,"median":-692.839373,"eighty":-89.564435,"marketCap":176870174},{"date":"2026-03-06","current":-57.446576,"twenty":-1274.188557,"median":-672.461744,"eighty":-85.125381,"marketCap":169180167},{"date":"2026-03-13","current":-56.140972,"twenty":-1274.111229,"median":-573.585372,"eighty":-82.019955,"marketCap":165335163},{"date":"2026-03-20","current":-46.740623,"twenty":-1273.601789,"median":-468.661403,"eighty":-78.07512,"marketCap":137651136},{"date":"2026-03-27","current":-52.746402,"twenty":-1273.601789,"median":-388.787461,"eighty":-70.812259,"marketCap":155338153},{"date":"2026-04-02","current":-59.535543,"twenty":-1261.875188,"median":-347.684797,"eighty":-63.609027,"marketCap":175332173},{"date":"2026-04-10","current":-69.980375,"twenty":-1239.272545,"median":-288.180044,"eighty":-63.922372,"marketCap":206092203},{"date":"2026-04-17","current":-67.630287,"twenty":-1224.997133,"median":-279.819872,"eighty":-64.39239,"marketCap":199171196},{"date":"2026-04-24","current":-59.274422,"twenty":-1219.804849,"median":-270.476151,"eighty":-63.086786,"marketCap":174563172},{"date":"2026-05-01","current":-59.274422,"twenty":-1218.712729,"median":-247.977452,"eighty":-60.266681,"marketCap":174563172},{"date":"2026-05-08","current":-53.529764,"twenty":-1181.046406,"median":-233.593039,"eighty":-59.483319,"marketCap":157645155},{"date":"2026-05-15","current":-54.313127,"twenty":-1158.867362,"median":-224.00343,"eighty":-58.073266,"marketCap":159952158},{"date":"2026-05-22","current":-34.243665,"twenty":-1148.331229,"median":-208.512523,"eighty":-57.133231,"marketCap":159952158},{"date":"2026-05-29","current":-35.757904,"twenty":-1142.675525,"median":-203.776286,"eighty":-56.297645,"marketCap":167025170},{"date":"2026-06-05","current":-33.374044,"twenty":-1134.700579,"median":-196.095209,"eighty":-56.036524,"marketCap":155890158},{"date":"2026-06-12","current":-27.096545,"twenty":-1121.197411,"median":-193.267504,"eighty":-54.992041,"marketCap":126567962},{"date":"2026-06-18","current":-25.427843,"twenty":-1108.804685,"median":-184.907332,"eighty":-54.417575,"marketCap":118773454},{"date":"2026-06-26","current":-30.195563,"twenty":-1095.428198,"median":-114.624161,"eighty":-53.529764,"marketCap":141043477},{"date":"2026-07-02","current":-32.579424,"twenty":-1082.986082,"median":-103.543825,"eighty":-52.746402,"marketCap":152178488},{"date":"2026-07-10","current":-36.552524,"twenty":-1060.672665,"median":-99.487025,"eighty":-51.754143,"marketCap":170736840},{"date":"2026-07-17","current":-36.552524,"twenty":-1055.204554,"median":-92.175643,"eighty":-49.821849,"marketCap":170736840},{"date":"2026-07-24","current":-43.068409,"twenty":-1041.194934,"median":-90.680447,"eighty":-46.740623,"marketCap":201172538},{"date":"2026-07-31","current":-35.440056,"twenty":-1035.692974,"median":-89.564435,"eighty":-44.129415,"marketCap":165540502},{"date":"2026-08-07","current":-32.102652,"twenty":-1023.721118,"median":-86.906434,"eighty":-41.955941,"marketCap":149951486},{"date":"2026-08-14","current":-32.738348,"twenty":-1022.39985,"median":-84.821879,"eighty":-38.384758,"marketCap":152920822},{"date":"2026-08-21","current":-34.327588,"twenty":-1020.43275,"median":-82.267064,"eighty":-36.552524,"marketCap":160344163},{"date":"2026-08-28","current":-36.552524,"twenty":-1003.088768,"median":-79.119603,"eighty":-35.916828,"marketCap":170736840},{"date":"2026-09-04","current":-36.075752,"twenty":-993.631023,"median":-76.226732,"eighty":-35.889995,"marketCap":168509838},{"date":"2026-09-08","current":-37.98284,"twenty":-992.924424,"median":-74.378344,"eighty":-35.895362,"marketCap":177417847}],"updateTime":1789024156800},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MENS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664871215","title":"Jyong Biotech to Join StockFan Virtual Investor Non-Deal Roadshow","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871215","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871215?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:02","pubTimestamp":1788436967,"startTime":"0","endTime":"0","summary":"Jyong Biotech to join StockFan virtual investor non-deal roadshowJyong Biotech will join a StockFan virtual investor non-deal roadshow on Sept. 6, 2026 (U.S. Eastern Time).The session runs 8:30 p.m.–9","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL6pP8W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BQXX3F31.USD","BK4585","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","IE00BN0W2W23.USD","SG9999014005.SGD","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","MENS","BK4139","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BCDF","IE00BQXX3D17.EUR","BK4112","IE00BQXX3C00.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014039.USD","NDAQ","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639788622","title":"Jyong Biotech CEO targets 2029-2030 FDA NDA filing for Botreso, PharmaBoardroom interview says","url":"https://stock-news.laohu8.com/highlight/detail?id=2639788622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639788622?lang=en_us&edition=fundamental","pubTime":"2026-05-29 20:05","pubTimestamp":1780056341,"startTime":"0","endTime":"0","summary":"Jyong Biotech CEO Fu-Feng Kuo outlined an FDA plan for Botreso, its lead botanical drug candidate for benign prostatic hyperplasia.Targeted combined NDA submission in 2029-2030, contingent on a US pharmacokinetic comparability study for API-1 versus API-2.Planned Phase III trial using API-2 to support supply-chain requirements for FDA review.Two pivotal studies, two one-year open-label extensions in the US and Taiwan cited as showing no emergent safety signals.US commercialization prioritized first, positioning FDA approval as a gateway for Brazil, Israel, and broader Asia.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL3498Xk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","MENS","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","SG9999014021.USD","NDAQ","BK4139","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU2210150020.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635835760","title":"Jyong Biotech FY25 net loss widens 55% to US$4.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635835760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635835760?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:19","pubTimestamp":1778840392,"startTime":"0","endTime":"0","summary":"Jyong Biotech posted a net loss of US $4.67 million, widening from US $3.02 million a year earlier.Operating loss widened to US $2.61 million as total operating expenses rose 27% to US $2.61 million.General and administrative costs climbed 61% to US $1.75 million, while research and development expense fell 12% to US $813,000.Interest expense more than doubled to US $2.54 million, while interest income rose to US $610,000 from US $7,000.Botreso API-2 CMC package was initially submitted to the U.S. FDA in October 2024, with updated Module 3 and stability data slated for submission in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7R481W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631544178","title":"Jyong Biotech delays annual Form 20-F filing, cites audit completion needs","url":"https://stock-news.laohu8.com/highlight/detail?id=2631544178","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631544178?lang=en_us&edition=fundamental","pubTime":"2026-04-30 01:12","pubTimestamp":1777482754,"startTime":"0","endTime":"0","summary":"Jyong Biotech filed a Form 12b-25 to notify investors it will miss deadline for its annual Form 20-F for fiscal year ended Dec. 31, 2025.Delay was attributed to additional time needed to finalize audited financial statements and related disclosures.Company expects to file Form 20-F on or before 15th calendar day following prescribed due date.Management indicated it does not expect a significant change in results of operations versus corresponding prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL11cggC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627440097","title":"Jyong Biotech files Form 3; CFO Zhang Wei reports no beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2627440097","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627440097?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:46","pubTimestamp":1776181616,"startTime":"0","endTime":"0","summary":"Jyong Biotech CFO Wei  Zhang filed an initial Form 3 insider ownership statement dated April 13, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLc0PtG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625947189","title":"Jyong Biotech files Form 3 showing CEO Fu-Feng Kuo as 10% owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2625947189","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625947189?lang=en_us&edition=fundamental","pubTime":"2026-04-08 22:12","pubTimestamp":1775657521,"startTime":"0","endTime":"0","summary":"Jyong Biotech CEO Fu-Feng Kuo filed an initial Form 3 as director, 10% owner.Kuo reported indirect ownership of 25,349,500 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLbDxSX2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624468595","title":"Jyong Biotech director Chi Pang-Chieh files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624468595","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624468595?lang=en_us&edition=fundamental","pubTime":"2026-04-02 02:57","pubTimestamp":1775069828,"startTime":"0","endTime":"0","summary":"Jyong Biotech filed an initial Form 3 naming Chi Pang-Chieh as a director on 04/01/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL134G6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MENS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622782971","title":"Jyong Biotech updates MCS-2 BPH/LUTS program; Phase III trials span 27 U.S. centers in 19 states","url":"https://stock-news.laohu8.com/highlight/detail?id=2622782971","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622782971?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:30","pubTimestamp":1774614624,"startTime":"0","endTime":"0","summary":"Jyong Biotech reported updated information on MCS-2, an investigational oral botanical drug candidate being studied for benign prostatic hyperplasia/lower urinary tract symptoms.The company said MCS-2 has completed four Phase III clinical trials in the U.S. and Taiwan, including two pivotal trials and two open-label extension studies.Jyong Biotech stated that the Phase III clinical trial report was completed in 2017, and the drug has not been approved for commercial use in any jurisdiction.The company reported that U.S. trials were conducted at 27 centers in 19 states, and Taiwan trials were conducted at 12 hospitals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL6KCYYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4588","BK4585","LU2210149790.SGD","LU2095319765.USD","MENS","IE00BN0W2W23.USD","SG9999014021.USD","BK4112","SG9999014039.USD","LU0314104364.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}]}}